You are here

Herzuma Approved for Treatment of Breast Cancer

New Biosimilar Provides Broader Treatment Options for Patients

The FDA has approved another biosimilar for the adjuvant treatment of HER2 overexpressing, node-positive or node-negative breast cancer. In addition, this biosimilar Herzuma (trastuzumab-pkrb, Celltrion, South Korea, and Teva Pharmaceutical, Israel) is approved as part of a first-line treatment for metastatic breast cancer combined with chemotherapy.

Common adverse events associated with the use of trastuzumab-pkrb for treatment of HER2-positive breast cancers include diarrhea, headache, chills, nausea, fever, infection, insomnia, congestive heart failure, cough and rash. Serious adverse effects can include worsening of chemotherapy-induced neutropenia.

Like its reference product trastuzumab (Herceptin, Genentech), trastuzumab-pkrb carries a boxed warning about elevated risks for cardiomyopathy, infusion reactions, pulmonary toxicity, and embryo-fetal toxicity.

Source: Biospace.com, December 17, 2018

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function